Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial
Rafael E de Feria Cardet, Michael S Hofman, Tatiana Segard, Jackie Yim, Scott Williams, Roslyn J Francis, Mark Frydenberg, Nathan Lawrentschuk, Declan G Murphy, Richard De Abreu Lourenco
EUROPEAN UROLOGY | ELSEVIER | Published : 2021
BACKGROUND: Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) into routine care, it is important to assess if the benefits justify the differences in resource use. OBJECTIVE: To determine the cost-effectiveness of PSMA-PET/CT when compared with conventional imaging. DESIGN, SETTING, AND PARTICIPANTS: A cost-effectiveness analysis was developed using data from the proPSMA study. proPSMA included patients with high-risk prostate cancer assigned to conventional imaging or 68Ga-PSMA-11 PET/CT with planned health economics data collected. The cost-effectiveness analysis was conducted from an Australian societal perspective. INTE..View full abstract
This investigator-initiated trial was funded by Movember and the Prostate Cancer Foundation of Australia and co-badged by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. The sponsor (Peter MacCallum Cancer Centre) and funders had no direct role in the study.